{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:08:41Z","timestamp":1790291321497,"version":"4.1.0"},"reference-count":94,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves' disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression\/worsening. In the presence of mild TED, any treatment for hyperthyroidism can be used, but should RAI treatment be selected, steroid prophylaxis (short course of low-dose prednisone) is strongly recommended if TED is of recent onset and\/or risk factors for progression exist. In moderate to severe and active TED, ATDs are the preferred treatment, but thyroidectomy is a valid option. RAI ablation is generally avoided; it might be used when the clinical situation calls for it, but with extreme caution, if an aggressive treatment for TED with high-dose glucocorticoids (with or without orbital radiotherapy) is administered concomitantly. In moderate to severe and inactive TED, all 3 treatments for hyperthyroidism are acceptable, and steroid prophylaxis in RAI-treated patients should be given when risk factors for TED progression are identified. Management of sight-threatening TED represents the absolute priority, and hyperthyroidism should be controlled with ATDs until TED has been controlled.<\/jats:p>\n                  <jats:p>Search Strategies<\/jats:p>\n                  <jats:p>Current guidelines, original articles, clinical trials, systematic reviews, and meta-analyses up to June 2024 were searched using the following terms: \u201cGraves' disease,\u201d \u201cmanagement of Graves' disease,\u201d \u201cantithyroid drugs,\u201d \u201cradioactive iodine,\u201d \u201cthyroidectomy,\u201d \u201cthyroid eye disease,\u201d \u201cGraves' orbitopathy or ophthalmopathy.\u201d<\/jats:p>","DOI":"10.1210\/clinem\/dgaf009","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:18:51Z","timestamp":1736378331000},"page":"922-930","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8447-5449","authenticated-orcid":false,"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[{"name":"The School of Medicine, University of Insubria , Varese 21100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-9685","authenticated-orcid":false,"given":"Terry J","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences and Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48105 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"16","key":"2025031717065112300_dgaf009-B1","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2025031717065112300_dgaf009-B2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves' orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J Intern Med"},{"issue":"2","key":"2025031717065112300_dgaf009-B3","first-page":"168","article-title":"Graves' ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"issue":"4","key":"2025031717065112300_dgaf009-B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of Graves' hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"4","key":"2025031717065112300_dgaf009-B5","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025031717065112300_dgaf009-B6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"issue":"5","key":"2025031717065112300_dgaf009-B7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2025031717065112300_dgaf009-B8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s40618-020-01479-z","article-title":"Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression","volume":"44","author":"Ippolito","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2025031717065112300_dgaf009-B9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","article-title":"Extrathyroidal manifestations of Graves' disease: a 2014 update","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"issue":"6S","key":"2025031717065112300_dgaf009-B10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid eye disease: epidemiology, natural history, and risk factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"2025031717065112300_dgaf009-B11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","article-title":"2021 update on thyroid-associated ophthalmopathy","volume":"45","author":"Neag","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"Supplement_1","key":"2025031717065112300_dgaf009-B12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/edrv-10-3-366","article-title":"Connective tissue, glycosaminoglycans, and diseases of the thyroid","volume":"10","author":"Smith","year":"1989","journal-title":"Endocr Rev"},{"issue":"9","key":"2025031717065112300_dgaf009-B14","first-page":"3428","article-title":"Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture","volume":"81","author":"Sorisky","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B15","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1210\/jc.2002-030010","article-title":"Pathophysiology of Graves' ophthalmopathy: the cycle of a disease","volume":"88","author":"Bahn","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025031717065112300_dgaf009-B16","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s40618-020-01258-w","article-title":"Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective, cross-sectional multicentre study","volume":"43","author":"Perros","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2025031717065112300_dgaf009-B17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/BF03350047","article-title":"More on smoking habits and Graves' ophthalmopathy","volume":"12","author":"Bartalena","year":"1989","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2025031717065112300_dgaf009-B18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves' disease","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"issue":"2","key":"2025031717065112300_dgaf009-B19","first-page":"185","article-title":"Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism","volume":"121","author":"Prummel","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"8664","key":"2025031717065112300_dgaf009-B20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(89)90945-8","article-title":"Ophthalmopathy and thyroid stimulation","volume":"2","author":"Karlsson","year":"1989","journal-title":"Lancet"},{"issue":"26","key":"2025031717065112300_dgaf009-B21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"issue":"2","key":"2025031717065112300_dgaf009-B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"2025031717065112300_dgaf009-B23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves' disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2025031717065112300_dgaf009-B24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves' disease","volume":"106","author":"Nilsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025031717065112300_dgaf009-B25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025031717065112300_dgaf009-B26","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","article-title":"Management of Graves thyroidal and extrathyroidal disease: an update","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/archopht.120.3.380","article-title":"Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy","volume":"120","author":"Kazim","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"18","key":"2025031717065112300_dgaf009-B28","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025031717065112300_dgaf009-B29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2025031717065112300_dgaf009-B30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(3)","key":"2025031717065112300_dgaf009-B31","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1210\/clinem\/dgae711","article-title":"The efficacy and safety of intravenous tocilizumab to treat graves' ophthalmopathy: a systematic review and single-arm meta-analysis","volume":"110","author":"Sun","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025031717065112300_dgaf009-B32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41574-024-01016-5","article-title":"Graves disease: latest understanding of pathogenesis and treatment options","volume":"20","author":"Lanzolla","year":"2024","journal-title":"Nature Rev Endocrinol"},{"issue":"12","key":"2025031717065112300_dgaf009-B33","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B34","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1210\/jc.2016-1220","article-title":"Thyroid stimulating antibodies are highly prevalent in Hashimoto's thyroiditis and associated orbitopathy","volume":"101","author":"Kahaly","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025031717065112300_dgaf009-B35","first-page":"473","article-title":"Studies on the occurrence of ophthalmopathy in Graves' disease","volume":"120","author":"Marcocci","year":"1989","journal-title":"Acta Endocrinol"},{"issue":"12","key":"2025031717065112300_dgaf009-B36","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves' disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025031717065112300_dgaf009-B37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves' disease","volume":"84","author":"Bartalena","year":"2016","journal-title":"Clin Endocrinol"},{"issue":"11","key":"2025031717065112300_dgaf009-B38","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A 2023 international survey of clinical practice patterns in the management of Graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025031717065112300_dgaf009-B39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/17446651.2022.2052044","article-title":"Management of Graves' hyperthyroidism: present and future","volume":"17","author":"Bartalena","year":"2022","journal-title":"Exp Rev Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/clinem\/dgad538","article-title":"Outcomes of patients with Graves disease 25 years after initiating antithyroid drug therapy","volume":"109","author":"Stokland","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025031717065112300_dgaf009-B41","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"4","key":"2025031717065112300_dgaf009-B42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eprac.2023.01.006","article-title":"Long-term follow-up of Graves orbitopathy after treatment with short- or long-term methimazole or radioactive iodine","volume":"29","author":"Azizi","year":"2023","journal-title":"Endocr Pract"},{"issue":"10","key":"2025031717065112300_dgaf009-B43","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1210\/clinem\/dgae456","article-title":"Approach to the patient considering long-term antithyroid drug therapy for Graves' disease","volume":"109","author":"Azizi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B44","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"Antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025031717065112300_dgaf009-B45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves' disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"issue":"5","key":"2025031717065112300_dgaf009-B46","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/cen.14719","article-title":"Post-radioiodine Graves' management: the PRAGMA study","volume":"97","author":"Perros","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"7","key":"2025031717065112300_dgaf009-B47","doi-asserted-by":"crossref","first-page":"e209660","DOI":"10.1001\/jamanetworkopen.2020.9660","article-title":"Association of radioiodine, antithyroid drug and surgical treatments with solid cancer mortality in patients with hyperthyroidism","volume":"3","author":"Kitahara","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2025031717065112300_dgaf009-B48","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1210\/clinem\/dgab700","article-title":"Does radioactive iodine therapy for hyperthyroidism cause cancer?","volume":"107","author":"Kim","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12209","article-title":"Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials","volume":"79","author":"Guo","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2025031717065112300_dgaf009-B50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/00000658-199809000-00005","article-title":"The importance of surgeon experience for clinical and economic outcomes from thyroidectomy","volume":"228","author":"Sosa","year":"1998","journal-title":"Ann Surg"},{"issue":"8","key":"2025031717065112300_dgaf009-B51","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B52","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","article-title":"Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids","volume":"92","author":"Menconi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025031717065112300_dgaf009-B53","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/jc.2013-3093","article-title":"Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial","volume":"99","author":"Moleti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025031717065112300_dgaf009-B54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","article-title":"The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study","volume":"51","author":"Marcocci","year":"1999","journal-title":"Clin Endocrinol"},{"issue":"2","key":"2025031717065112300_dgaf009-B55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000444796","article-title":"Comparison of early total thyroidectomy with antithyroid treatment in patients with moderate-severe Graves' orbitopathy: a randomized prospective trial","volume":"5","author":"Erdogan","year":"2016","journal-title":"Eur Thyroid J"},{"issue":"(07|7)","key":"2025031717065112300_dgaf009-B56","first-page":"433","article-title":"The effect of early thyroidectomy on the course of active Graves' orbitopathy (GO): a retrospective case study","volume":"48","author":"Meyer Zu Horste","year":"2016","journal-title":"Horm Metab Res"},{"issue":"2","key":"2025031717065112300_dgaf009-B57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40618-020-01320-7","article-title":"Antithyroid drugs in Graves' hyperthyroidism: differences between \u201cblock and replace\u201d and \u201ctitration\u201d regimes in frequency of euthyroidism and Graves' orbitopathy during treatment","volume":"44","author":"Zarkovic","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2025031717065112300_dgaf009-B58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2265.2008.03279.x","article-title":"Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review","volume":"69","author":"Acharya","year":"2008","journal-title":"Clin Endocrinol"},{"issue":"10","key":"2025031717065112300_dgaf009-B59","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1210\/jc.2009-0747","article-title":"Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131","volume":"94","author":"Traisk","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025031717065112300_dgaf009-B60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1064","key":"2025031717065112300_dgaf009-B61","doi-asserted-by":"crossref","first-page":"20160418","DOI":"10.1259\/bjr.20160418","article-title":"Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials","volume":"89","author":"Wang","year":"2016","journal-title":"Br J Radiol"},{"issue":"2","key":"2025031717065112300_dgaf009-B62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/wjs.12066","article-title":"A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: a Bayesian network meta-analysis","volume":"48","author":"Liu","year":"2024","journal-title":"World J Surg"},{"issue":"3","key":"2025031717065112300_dgaf009-B63","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s12020-021-02952-2","article-title":"Increased risk of Graves' ophthalmopathy in patients with increased TRAb and the impact of CTLA4 on TRAb titres","volume":"75","author":"Shahida","year":"2022","journal-title":"Endocrine"},{"issue":"9","key":"2025031717065112300_dgaf009-B64","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2009-0506","article-title":"Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis","volume":"94","author":"Vannucchi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025031717065112300_dgaf009-B65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","article-title":"Cigarette smoking and treatment outcomes in Graves ophthalmopathy","volume":"129","author":"Bartalena","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"2025031717065112300_dgaf009-B66","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","article-title":"Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?","volume":"130","author":"Tallstedt","year":"1994","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025031717065112300_dgaf009-B67","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1210\/jc.2005-0507","article-title":"A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy","volume":"90","author":"Perros","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025031717065112300_dgaf009-B68","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1089\/thy.2019.0150","article-title":"Prevention of orbitopathy by intravenous steroid prophylaxis in short duration Graves' disease patients undergoing radioiodine ablation: a prospective randomized control trial study","volume":"29","author":"Vannucchi","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"2025031717065112300_dgaf009-B69","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2009-2130","article-title":"Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study","volume":"95","author":"Lai","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40618-019-01126-2","article-title":"Oral steroid prophylaxis after radioactive iodine treatment for Graves' disease is not only effetive, but also safe","volume":"43","author":"Rosetti","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2025031717065112300_dgaf009-B71","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjsurg.2005.10.043","article-title":"Thyroidectomy remains an effective treatment option for Graves' disease","volume":"191","author":"Weber","year":"2006","journal-title":"Am J Surg"},{"issue":"4","key":"2025031717065112300_dgaf009-B72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2967\/jnumed.122.264660","article-title":"Radioiodine ablation of thyroid remnants in Graves' orbitopathy","volume":"64","author":"Oeverhaus","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"2025031717065112300_dgaf009-B73","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1210\/jc.2011-2077","article-title":"Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial","volume":"97","author":"Leo","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025031717065112300_dgaf009-B74","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1442-9071.2004.00756.x","article-title":"Late reactivation of thyroid orbitopathy","volume":"32","author":"Selva","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"2025031717065112300_dgaf009-B75","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","article-title":"The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy","volume":"96","author":"Bartalena","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"2025031717065112300_dgaf009-B76","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2025031717065112300_dgaf009-B77","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025031717065112300_dgaf009-B78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1210\/endrev\/bnae018","article-title":"Teprotumumab for the treatment of thyroid eye disease","volume":"45","author":"Ugradar","year":"2024","journal-title":"Endocr Rev"},{"issue":"7","key":"2025031717065112300_dgaf009-B79","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2025031717065112300_dgaf009-B80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/IOP.0000000000002531","article-title":"Proptosis regression after teprotumumab treatment for thyroid eye disease","volume":"40","author":"Rosenblatt","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"2025031717065112300_dgaf009-B81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B82","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid"},{"issue":"6","key":"2025031717065112300_dgaf009-B83","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism","volume":"178","author":"Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025031717065112300_dgaf009-B84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025031717065112300_dgaf009-B85","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025031717065112300_dgaf009-B86","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab-exploratory trial in young people with Graves disease","volume":"107","author":"Cheetham","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025031717065112300_dgaf009-B87","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"issue":"6","key":"2025031717065112300_dgaf009-B88","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy\u2014results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2025031717065112300_dgaf009-B89","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"2025031717065112300_dgaf009-B90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"},{"issue":"3","key":"2025031717065112300_dgaf009-B91","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD-40 monoclonal antibody, iscalimab, for control of Graves'hyperthyroidism\u2014a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2025031717065112300_dgaf009-B92","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1074\/jbc.M111246200","article-title":"Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in orbital human fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathion-dependent prostaglandin E2 synthase expression","volume":"277","author":"Han","year":"2002","journal-title":"J Biol Chem"},{"issue":"45","key":"2025031717065112300_dgaf009-B93","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.273.45.29615","article-title":"Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy","volume":"273","author":"Cao","year":"1998","journal-title":"J Biol Chem"},{"issue":"12","key":"2025031717065112300_dgaf009-B94","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1089\/thy.2016.0243","article-title":"Thyrotropin and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid-associated ophthalmopathy","volume":"26","author":"Wu","year":"2016","journal-title":"Thyroid"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf009\/61398040\/dgaf009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/4\/922\/61398040\/dgaf009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/4\/922\/61398040\/dgaf009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:07:22Z","timestamp":1742216842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/4\/922\/7950764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,9]]},"published-print":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf009","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,1,9]]}}}